Navigation Links
University of South Florida receives new multimillion award to assess juvenile diabetes treatments
Date:7/31/2008

Tampa, FL (July 31, 2008) -- The National Institutes of Health has awarded $128 million to the University of South Florida research team led by Jeffrey Krischer, PhD, to coordinate worldwide studies on the prevention and treatment of juvenile diabetes. This latest funding, a seven-year award, supports Dr. Krischer's coordination of the NIH network of clinical research centers known as TrialNet.

The award adds to the $169 million received last year by Dr. Krischer, a professor of pediatrics, to coordinate studies examining the causes of juvenile diabetes. That previously funded 10-year NIH study, known as TEDDY (The Environmental Determinants of Diabetes in the Young), is seeking to explain why the incidence of diabetes in the very young has doubled since the 1980s. The $169-million grant was the largest in USF's history.

"Dr. Krischer's new TrialNet grant will catapult USF to the top 50 for NIH funding to medical schools," said Stephen Klasko, MD, MBA, senior vice president for USF Health and dean of the College of Medicine. "Almost every major effort worldwide to eliminate type 1 diabetes for the next generation comes through here."

"Jeff sees connections other people don't see. He uses tools in new ways to solve very complex problems," said Karen Holbrook, PhD, vice president for research and innovation at USF. "It's an extraordinary program that is doing as much as any program today for people around the globe. It is innovative, and it is important."

Type 1 diabetes, also known as juvenile diabetes, is one of the most common and serious long-term diseases in children and adolescents. It is a disease in which the body's immune system attacks the cells that make insulin a hormone that keeps blood sugar levels stable. Its treatment requires a life-long commitment to daily insulin injections and significant lifestyle changes.

TrialNet will screen more than 150,000 children and adults, identifying those with early signs of diabetes to investigate new therapies that may arrest disease progression. Other studies include treatments of newly diagnosed patients to prevent continued loss of insulin production capability. These treatments, if proven successful, may be tested to determine if they can yield new prevention strategies. In addition to heading the data coordinating and technology center for TrialNet, Dr. Krischer chairs one of the major prevention studies within the consortium a clinical trial investigating whether oral insulin can prevent or delay diabetes in a specific group of people at risk for type 1 diabetes.

TEDDY is screening more than 300,000 newborns and following 8,000 for up to 15 years to investigate the role that diet, infections, and other environmental factors may play in the disease process. Dr. Krischer chairs the study itself as well as directing TEDDY's data coordinating center.

Both TrialNet and TEDDY are being carried out on an international stage through clinical sites in the United States, Canada, Europe, Australia and New Zealand

The two projects complement each other, with virtually every major university and medical center conducting type 1 diabetes research now linked to Dr. Krischer's Pediatric Epidemiology Center at USF. The center is pooling the clinical consortiums' efforts to understand the triggers of diabetes and to develop strategies to prevent or improve treatment. Data describing the everyday lives of study participants, results from research laboratories across the globe, and the clinical course of the disease in affected individuals flow into USF on a continual basis.

All that data is analyzed at USF and shared with scientists, clinicians and investigators worldwide with the goal of putting an end to type 1 diabetes, Dr. Krischer said. "This team effort would not be possible without the outstanding group of 50-plus researchers at USF working on these studies. They are recognized world experts in developing new technologies and informatics applied to medicine," he said. "The research in diabetes complements our other projects in rare diseases, many of which are also autoimmune diseases and share a common etiological pathway. The hope is that our efforts can lead to improvements for all those affected."


'/>"/>

Contact: Anne DeLotto Baier
abaier@health.usf.edu
813-974-3300
University of South Florida Health
Source:Eurekalert  

Related medicine news :

1. Georgetown University Medical Center Collaborates with Indivumed to Develop Cancer Research Database
2. ARUP Laboratories and Weber State University Announce Educational Collaboration
3. The Doctors Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team
4. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
5. InfoLogix Selected by University Medical Center to Deploy Mobile Wireless Asset Tracking Solution
6. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
7. Capella University Launches Online PhD Specialization in Nursing Education
8. Nations Fourth Hand Transplant Performed at Jewish Hospital Hand Care Center by Kleinert Kutz and University of Louisville Surgeons
9. University of Cincinnati professor receives Neuroradiology Societys highest honor
10. Temple University Hospital Ranked Among Best in America for Respiratory Disorders by U.S. News & World Report
11. Howard University and CVS/pharmacy Announce Ribbon Cutting for the Howard University Pharmacy Practice Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
University of South Florida receives new multimillion award to assess juvenile diabetes treatments
(Date:2/24/2017)... ... , ... An in-depth computational analysis of genetic variants implicated in both schizophrenia ... that may explain why susceptibility to one of the disorders could place individuals at ... in the journal npj Schizophrenia. , “There is a wealth of genomic data ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT ... top priority because it’s not if you will be attacked, but when.” However, he ... comes to digital health care. , Improvements in auditing and monitoring have taken security ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he ... and his attempts to overcome them. , Schanssema, initially unsure of the career path ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... Prophecy concerning this present generation. Yisrayl makes an astounding statement when he says ... He explains that the Bible details the current times so plainly that anyone should ...
(Date:2/24/2017)... ... , ... The Radiology Business Management Association will select the 2017 ... Building Better Radiology Marketing Programs conference, held this year from March 5 ... awards are given out in five categories. They are:, ,     Patient ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
Breaking Medicine Technology: